Ken Herrmann

Jan 10, 2025 | urotoday.com | Ken Herrmann

Read the Full Video TranscriptOliver Sartor: Hi, I'm Dr. Oliver Sartor. I'm here with UroToday. And a real pleasure to be able to welcome Ken Herrmann. I think Ken Herrmann is known to almost everybody in the theranostics field. He's the Chairman of the Department of Nuclear Medicine at the University Hospital Essen, Essen, Germany. And Ken, are you going to be talking to us about some tumor dosimetry? A really interesting substudy from the VISION trial. So I'd love to hear your perspective on this.

Oct 1, 2024 | urotoday.com | Ken Herrmann

Read the Full Video TranscriptOliver Sartor: Hi, I'm Dr. Oliver Sartor, and really a pleasure today to be able to welcome Ken Herrmann on UroToday, one of the leading lights in the world and chairman of the German Nuclear Medicine Department at Essen, a professor there. Welcome, Ken. Ken Herrmann: Thank you very much, Oliver. It's a great honor to be with one of the big godfathers of radionuclide therapy in a conversation, Oliver.

Oct 1, 2024 | urotoday.com | Ken Herrmann

Read the Full Video TranscriptOliver Sartor: Hi, I'm Dr. Oliver Sartor, and really a pleasure today to be able to welcome Ken Herrmann on UroToday, one of the leading lights in the world and chairman of the German Nuclear Medicine Department at Essen, a professor there. Welcome, Ken. Ken Herrmann: Thank you very much, Oliver. It's a great honor to be with one of the big godfathers of radionuclide therapy in a conversation, Oliver.

Feb 1, 2024 | jnm.snmjournals.org | Oliver Sartor |Karim Fizazi |Ken Herrmann |Michael Morris

Thank you for your interest in spreading the word on Journal of Nuclear Medicine. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas.

Jun 21, 2023 | urotoday.com | Ken Herrmann

Read the Full Video TranscriptPhillip Koo: Welcome to UroToday, and our coverage of ASCO 2023. We're very privileged to have with us Dr. Ken Herrmann from University of Essen, who's presenting data regarding a predictive model for Lutetium-177-PSMA. Thank you for joining us. Before we get into to the data that you're presenting, can we talk a little bit about what is a prognostic tool versus a predictive tool? Ken Herrmann: That's an excellent question. So the prognostic tool mainly says...